Using Neratinib for Early HER2 Positive Breast Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the efficacy and safety of sequential neratinib therapy in patients with early HER2 positive breast cancer. It will involve a retrospective recruitment of patients treated at Peking University People's Hospital from January 2019 to November 2024, followed by prospective recruitment until December 2028. The study will compare the outcomes of patients who received standard anti-HER2 therapies followed by neratinib against those who did not. The primary endpoint is the 5-year invasive disease-free survival rate.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Patients with HER2 positive breast cancer who were diagnosed by core needle biopsy/operation in Peking University People's hospital;
* 2\) The patients were treated in our hospital and underwent radical resection with hospitalization records;
* 3\) Received standard anti-HER2 neoadjuvant/adjuvant therapy (trastuzumab, trastuzumab combined with pertuzumab, T-DM1)
* 4\) Has signed and agreed to participate in the PKUPH breast disease cohort study.

Exclusion Criteria:

* 1\) Lack of clinical and pathological data (such as imaging data and pathological data);
* 2\) Patients with metastatic breast cancer or bilateral breast cancer;
* 3\) Failure to perform radical surgery

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: shu wang, doctor — Peking University People's Hospital
• Study coordinator: yuan peng, doctor
• Email: 13671287670@163.com
• Phone: 86+13671287670

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• T-DXd with or without Neratinib for HER2-positive breast cancer with brain metastases

  This trial tests whether adding Neratinib to Trastuzumab Deruxtecan helps treat HER2-positive breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07152782

• Probiotics to prevent neratinib-related diarrhea in HER2-positive breast cancer patients

  This trial will test whether taking probiotics alongside standard preventive loperamide can reduce diarrhea in people with HER2-positive breast cancer who are starting neratinib compared with placebo.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06892093

• Treatment for hormone receptor positive HER2 positive breast cancer after neoadjuvant therapy

  This study is testing if combining two drugs, trastuzumab and nelatinib, can help people with hormone receptor positive HER2 positive breast cancer who still have cancer after initial treatment feel better compared to the usual combination of trastuzumab and pertuzumab.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou · NCT05760612

• Using Kadcyla and Neratinib to Treat Early HER2-positive Breast Cancer with Residual Disease

  This study is testing if adding a pill called neratinib to the standard treatment can help people with early HER2-positive breast cancer who still have some cancer cells left after their initial therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT05388149

• Pre-operative treatment for HER2-positive, ER-positive breast cancer

  This study is testing if a new combination of treatments can help women with HER2-positive, ER-positive breast cancer before they have surgery.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Chicago, Illinois and 3 other locations · NCT04886531

• Can we skip radiation after lumpectomy for low-risk HER2-positive breast cancer?

  This study tests whether patients who had breast-conserving surgery and low-risk HER2-positive breast cancer can safely skip radiation therapy while receiving HER2-targeted treatment.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895511

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.